MedCity News January 14, 2026
Executives from Merck, GE Healthcare and Alnylam Pharmaceuticals discuss past hurdles and how it has scrambled supply chains and clinical trial program. One warned about the effects of isolating China.
The life sciences industry in the U.S., and perhaps globally, is typically most concerned with market risk. That perspective has shifted tremendously as wars, changing regulations, policy upheavals, and a global pandemic have scrambled expectations.
On Tuesday, a panel of biotech operators from well-known life sciences companies in the U.S. and overseas explained how each of them are wrestling with geopolitical change and the lessons from the past few years. The event was organized by consulting firm BCG during JPM Week in San Francisco.
Pushkal Garg, chief R&D officer, Alnylam
...Today's Sponsors
Today's Sponsor